AIM ImmunoTech (AIM) vs CollPlant Biotechnologies (CLGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CollPlant Biotechnologies is the larger company by market cap ($7.5 million vs $7.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | CLGN |
|---|---|---|
| Share price | $0.1796 | $3.97 |
| Market cap | $7.17M | $7.51M |
| 1-day change | -1.75% | +14.74% |
| EPS (TTM) | $-2.98 | $-10.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $26.80 |
| 52-week low | $0.17 | $2.64 |
| Distance from 52-week high | -93.57% | -85.19% |
| Analyst consensus | none | — |
| Avg. price target upside | +2266.37% | — |
| Average volume | 4.70M | 351.98K |
| Shares outstanding | 39.89M | 1.89M |
| Employees | 19 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Healthcare · Biotechnology · 19 employees
About CollPlant Biotechnologies
CLGN stock →CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Healthcare · Biotechnology · 39 employees
AIM vs CLGN FAQ
Which is bigger, AIM ImmunoTech or CollPlant Biotechnologies?
CollPlant Biotechnologies (CLGN) is larger, with a market capitalization of $7.51M compared with $7.17M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and CollPlant Biotechnologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.